Skip to main content

Table 1 Response rates of an IBDV therapeutic vaccine on acute HBV and HCV infections

From: Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs

Response

HBV

HCV

 

IBDV

control

IBDV

control

Progression into CAHb

0/20 (0%)

3/23*a (13%)

2/22 (9%)

5/19* (26%)

Relapses

1/20 (5%)

2/23 (9%)

7/22 (32%)

15/19*** (79%)

Late remissionc

0/20 (0%)

4/23** (17%)

3/22 (14%)

8/19** (42%)

Fast remissiond

10/20 (50%)

6/23 (26%)

11/22 (50%)

4/19 (21%)

Duratione (weeks ± SD)

5.9 ± 3.0

7.5 ± 3.7

5.3 ± 4.4

8.9 ± 7.4

  1. aSignificance (p value, chi-square, Yates’ correction): *p < 0.05; **p < 0.02; ***p < 0.01;
  2. bChronic active hepatitis
  3. cRemission over 6 months
  4. dRemission within 1 month
  5. eDuration of the first icteric phase
Back to article page

Hepatology, Medicine and Policy

ISSN: 2059-5166

Contact us